The DOI matches its Crossref record.
Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
Abstract
Abstract LY2835219 is a novel cell cycle inhibitor selective for the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6), which act in a protein complex with D-type cyclins to enable G1 to S cell cycle progression. Preclinical models indicate this complex plays a critical role in breast cancer. We conducted a phase I study with expansion cohorts to evaluate the safety, pharmacokinetics, and antitumor activity of LY2835219 in 5 different tumor types: glioblastoma; melanoma; and cancers of the lung, colon/rectum and breast. In the expansion cohorts, LY2835219 was administered continuously at 150-200mg orally every 12 hours on Days 1-28 of a 28-day cycle. RECIST v1.1 was used to assess tumor response. The most common possibly related treatment-emergent adverse events across the expansion cohorts (n=132) included diarrhea (5% G3/4), nausea (3% G3/4), fatigue (2% G3/4), vomiting (2% G3/4) and neutropenia (11% G3/4). In the metastatic breast cancer (MBC) cohort, 47 patients with a median of 7 prior systemic regimens received therapy with LY2835219. Across all MBC patients, 9 achieved a best overall response of confirmed partial response (PR), 24 achieved stable disease (SD), 11 had progressive disease (PD), and 3 were not evaluable for response. Among the 36 HR+ patients, there were 9 confirmed partial responses for an ORR of 25%. In addition, 20 of these 36 HR+ patients (56%) had SD: 7 patients had SD < 24 weeks and 13 patients (including 2 patients with unconfirmed PR) had SD ≥ 24 weeks. The disease control rate (DCR = CR + PR + SD) was 70% for all patients and 81% for HR+ patients. The median PFS was 5.8 months for all patients and 9.1 months for HR+ patients, with 18 HR+ patients (including the 2 unconfirmed PRs) still on LY2835219 therapy (range: 2.8-15.5 months). In conclusion, LY2835219 demonstrates evidence of durable single-agent activity for women with MBC after multiple prior systemic regimens for metastatic disease, particularly for those women with HR+ tumors, and merits further clinical investigation in MBC. Citation Format: Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, Scott P. Myrand, Palaniappan Kulanthaivel, Lily Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr CT232. doi:10.1158/1538-7445.AM2014-CT232
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“among 25 patients with HR+/HER2− disease, the clinical benefit rate was 72%, including 7 partial responses (28%)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [95]
In the citing paper
“Although dose reductions for fatigue and diarrhea from 200 to 150 mg twice daily occurred, 150 mg still produced pharmacodynamic CDK4/6 inhibition and was administered continuously without interruption”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [95]
In the citing paper
“Importantly, activity was observed irrespective of concomitant PIK3CA mutation.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [95]
In the citing paper
“among four patients with HR−/HER2− cancers, all still had progressive disease”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [95]
In the citing paper
“for the entire HR+ population treated with abemaciclib, the median duration of response was 13.4 months and median PFS was 8.8 months.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [95]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Self-citationGelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Self-citationTargeting CDK4/6 in patients with cancer
Hamilton, E., & Infante, J. R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.002 · Cited by 481
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
Metadata
- Authors
- Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., Li, L., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y., & Shapiro, G. I.
- Affiliations
- South Texas Accelerated Research Therapeutics (US)
- University of California, Los Angeles (US)
- Dana-Farber Cancer Institute (US)
- Eli Lilly (United States) (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2014-10-01
- Volume
- 74
- Issue
- 19_Supplement
- Pages
- CT232-CT232
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2007112340
- Cited by
- 44
- References
- 0
- Citations by year
- 2025: 2 · 2022: 1 · 2019: 1 · 2018: 6 · 2017: 4 · 2016: 9 · 2015: 14 · 2014: 6
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6 inhibitors, metastatic breast cancer, cell cycle inhibitors, D-type cyclins, G1/S cell cycle progression, hormone receptor-positive breast cancer, anticancer activity, safety and tolerability, neutropenia, progression-free survival, disease control rate, oral administration, glioblastoma, melanoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. https://app.cochat.ai/papers/10.1158/1538-7445.am2014-ct232
- The paper
- Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., Li, L., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y., & Shapiro, G. I. (2014). Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. Cancer Research. https://doi.org/10.1158/1538-7445.am2014-ct232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.